Licensed vaccine
Flulaval Quadrivalent
FDA-licensed vaccine · ID Biomedical Corporation of Quebec · STN BL 125163
Key facts
| Trade name | Flulaval Quadrivalent |
|---|---|
| Proper name | Influenza Vaccine |
| Manufacturer | ID Biomedical Corporation of Quebec |
| Submission tracking number (STN) | BL 125163 |
| FDA product areas | Animal & Veterinary, Biologics, Vaccines |
| Recent FDA documents | July 13, 2023 Approval Letter - FLULAVAL QUADRIVALENT, July 1, 2022 Approval Letter - FluLaval Quadrivalent, July 2, 2021 Approval Letter - FluLaval, July 2, 2020 Approval Letter - FluLaval, February 6, 2020 Approval Letter - FluLaval, July 2, 2019 Approval Letter - FluLaval, Package Insert - FLULAVAL QUADRIVALENT, June 29, 2018 Approval Letter - FluLaval Quadrivalent, July 7, 2017 Approval Letter - FluLaval Quadrivalent, Clinical Review - FluLaval and FluLaval Quadrivalent, Statistical Review Assay - FluLaval and FluLaval Quadrivalent, Statistical Review and Evaluation - FluLaval and FluLaval Quadrivalent |
| FDA page updated | Jul 25, 2023 |
| FDA product page | fda.gov |
At a glance
- 1–9 FDA approval letters
- 10–99 Supporting documents
- 1–9 Product information documents
- Yes Document full text searchable in Orca1
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA-licensed vaccines
The FDA's CBER licenses vaccines for use in the United States. Each product page links the approval letters, package inserts and supporting documents for that vaccine.
Source: U.S. Food and Drug Administration (FDA), Center for Biologics Evaluation and Research (CBER), Vaccines Licensed for Use in the United States · Source date: